ARTICLES BY JANET LAMBERT
Why We Need A New Model To Appropriately Value The Promise Of Regenerative Medicines & Advanced Therapies7/27/2020
With durable or curative therapies near at hand for a range of severe diseases and disorders, it has become clear that payors need a different model for assessing the value of these innovative treatments.
Creating A Roadmap For The Development And Manufacture Of Gene Therapies5/4/2020
The cell and gene therapy sector is in need of a similar revolution, but instead of a “standard gauge,” there is a need for clear, evidence-based industry standards and best practices for manufacturing these innovative technologies.
State Of The Cell And Gene Therapy Sector — Clinical, Financial, And Regulatory Perspectives10/4/2018
The regenerative medicine sector is at a remarkable moment. Transformative products are now on the market and accessible to greater numbers of patients every day. Dozens of additional therapies are in late stage studies. The regulatory and policy environment has evolved rapidly alongside the science, enabling a surge of incoming innovation.